Anti-SARS-CoV-2 antibody inhibits variants of concern

by Dolly the Sheep | Aug 10, 2021 | COVID-19, Immunotherapy, in vivo Studies

Overview bioRxiv has recently released a preprint discussing a compelling neutralizing anti-SARS-CoV-2 antibody that hinders variants of concern. The authors identified one monoclonal antibody (mAB), the SARS2-38, powerfully neutralizes all SARS-CoV-2 variants of...

5 reasons why ribonucleoproteins are a better alternative to CRISPR plasmids

by Dolly the Sheep | Jul 28, 2021 | CRISRP

Dr. Brittany Enzmann from Synthego has recently published an article discussing about why ribonucleoprotein (RNP) is a better alternative to CRISPR plasmids for CRISPR genome editing experiments. Below are highlights from the article: 1. RNPs Reduce the Total...

How CRISPR editing is advancing cancer cell line research

by Dolly the Sheep | Jul 28, 2021 | Cancer, CRISRP

Dr. Rebecca Roberts from Synthego has recently published an article discussing applications of CRISPR in cancer cell lines and how CRISPR editing is advancing cancer cell line research. The advent of CRISPR genome engineering technology has enabled many breakthroughs...

[Webinar] Illumina – Mission Bio on novel somatic mutations

by Dolly the Sheep | Jul 21, 2021 | News, NGS, Single Cell

Webinar: Multiple Somatic Mutations Synergize to Drive Cerebral Cavernous Malformations   In this webinar, Daniel Snellings from the Duke University Medical Centre shares the role of somatic mutations in the pathogenesis of vascular malformations with specific...

How PDL1-PD1 immune checkpoint inhibits T cell activation

by Dolly the Sheep | Jul 12, 2021 | Cancer, in vivo Studies

Overview Science Advance has recently published a research article discussing how the PDL1-PD1 immune checkpoint inhibits T cell activation. Checkpoint immunotherapy is known to be a revolutionizing treatment for previously refractive tumors. However, researchers had...